ARV-766

· Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ARV-766, covering 2025-03-17 to 2025-03-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer [Phase 1, Phase 2]